Advertisement

AAPS PharmSciTech

, Volume 19, Issue 5, pp 2358–2369 | Cite as

Investigation of Cyclodextrin-Based Nanosponges for Solubility and Bioavailability Enhancement of Rilpivirine

  • Monica R. P. Rao
  • Jagruti Chaudhari
  • Francesco Trotta
  • Fabrizio Caldera
Research Article

Abstract

Rilpivrine is BCS class II drug used for treatment of HIV infection. The drug has low aqueous solubility (0.0166 mg/ml) and dissolution rate leading to low bioavailability (32%). Aim of this work was to enhance solubility and dissolution of rilpivirine using beta-cyclodextrin-based nanosponges. These nanosponges are biocompatible nanoporous particles having high loading capacity to form supramolecular inclusion and non-inclusion complexes with hydrophilic and lipophilic drugs for solubility enhancement. Beta-cyclodextrin was crosslinked with carbonyl diimidazole and pyromellitic dianhydride to prepare nanosponges. The nanosponges were loaded with rilpivirine by solvent evaporation method. Binary and ternary complexes of drug with β-CD, HP-β-CD, nanosponges, and tocopherol polyethylene glycol succinate were prepared and characterized by phase solubility, saturation solubility in different media, in vitro dissolution, and in vivo pharmacokinetics. Spectral analysis by Fourier transform infrared spectroscopy, powder X-ray diffraction, and differential scanning calorimetry was performed. Results obtained from spectral characterization confirmed inclusion complexation. Phase solubility studies indicated stable complex formation. Saturation solubility was found to be 10–13-folds higher with ternary complexes in distilled water and 12–14-fold higher in 0.1 N HCl. Solubility enhancement was evident in biorelevant media. Molecular modeling studies revealed possible mode of entrapment of rilpivirine within β-CD cavities. A 3-fold increase in dissolution with ternary complexes was observed. Animal studies revealed nearly 2-fold increase in oral bioavailability of rilpivirine. It was inferred that electronic interactions, hydrogen bonding, and van der Waals forces are involved in the supramolecular interactions.

KEY WORDS

bioavailability nanosponges beta-cyclodextrin inclusion complex rilpivirine 

Notes

Acknowledgements

The authors would like to thank Dr. Ashwini Madgulkar Principal, AISSMS College of Pharmacy, Pune-01, Maharashtra (India) for providing necessary help and facilities to carry out the research work and also thankful to Mylan Laboratories, Hyderabad (India) for providing drug as gift sample.

Compliance with Ethical Standards

Approval to carry out in vivo studies was obtained from Institutional Animal Ethics Committee, AISSMS College of Pharmacy (Approval from: AISSMS/CPCSEA/IAEC/PT-01/02/2K17) and their guidelines were followed for the studies.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Neslihan G, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drug. Biomed Pharmacotherapy. 2004;58:173–82.CrossRefGoogle Scholar
  2. 2.
    Enin A, Hadel A. Self-nanoemulsifying drug-delivery system for improved oral bioavailability of rosuvastatin using natural oil antihyperlipidemic. Drug Dev Ind Pharm. 2014;41(7):1047–56.CrossRefGoogle Scholar
  3. 3.
    Gao P, Guyton M, Huang T, Bauer J, Stefanski K. Enhanced oral bioavailability of a poorly water soluble drug by supersaturatable formulations. Drug Dev Ind Pharm. 2004;30(2):221–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhu J, Tang D, Feng L. Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride. Drug Dev Ind Pharm. 2013;39(3):499–506.CrossRefPubMedGoogle Scholar
  5. 5.
    Peri D, Cleary R, Wyandt M, Jones A. Inclusion complexes of tolnaftate with β-cyclodextrin and hydroxypropyl β-cyclodextrin. Drug Dev Ind Pharm. 2008;20(8):1401–10.CrossRefGoogle Scholar
  6. 6.
    Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponge for drug delivery. J Inclusion Phenom Macrocyclic Chem. 2006;56:209–13.CrossRefGoogle Scholar
  7. 7.
    Gursalkar T, Bajaj A, Jain D. Cyclodextrin based nanosponges for pharmaceutical use. Acta Pharm. 2013;63:335–58.CrossRefGoogle Scholar
  8. 8.
    Holvoet C, Vander Y, Plaizier J. Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use. Drug Dev Ind Pharm. 2005;31(6):567–75.CrossRefPubMedGoogle Scholar
  9. 9.
    Sanghavi M, Choudhari K, Matharu R, Viswanathan L. Inclusion complexation of lorazepam with β-cyclodextrin. Drug Dev Ind Pharm. 1993;19(6):701–12.CrossRefGoogle Scholar
  10. 10.
    Pravin S, Yogesh K, Gaud RS, Kiran D, Roberta C, Francesco T, et al. Acute and repeated dose toxicity studies of different β-cyclodextrin-based nanosponge formulations. J Pharm Sci. 2015;104:1856–63.CrossRefGoogle Scholar
  11. 11.
    Swaminathan S, Racalli R, Trotta F. Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development. WIREs Nanomed Nanobiotechnol. 2016;8:579–601.CrossRefGoogle Scholar
  12. 12.
    Ahmed A, Patil G, Zaheer Z. Nanosponges—a completely new nano-horizon: pharmaceutical applications and recent advances. Drug Dev Ind Pharm. 2013;39(9):1263–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Christian F, Mehrdad Y, Claudio O. Inclusion and functionalization of polymers with cyclodextrins: current applications and future prospects. Molecules. 2014;19:1466–79.Google Scholar
  14. 14.
    Gidwani B, Vyas A. A comprehensive review on cyclodextrin based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. Bio Med Res Int. 2015;15:1–15.Google Scholar
  15. 15.
    Rao M, Bajaj A, Khole I, Munjapara G, Trotta F. In vitro and in vivo evaluation of β-cyclodextrin based nanosponges of telmisartan. J Inclusion Phenom Macrocyclic Chem. 2013;77(4):135–45.CrossRefGoogle Scholar
  16. 16.
    Zhong L, Zhu X, Yu B, Su W. Influence of alkalizers on dissolution properties of telmisartan in solid dispersions prepared by co-grinding. Drug Dev Ind Pharm. 2014;40:1660–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Shende P, Gaud R, Bakal R, Patil D. Effect of inclusion complexation of meloxicam with betacyclodextrin-and beta-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies. Colloids Surf, B. 2015;15:1–26.Google Scholar
  18. 18.
    El-Badry M, Fathy M. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinyl pyrrolidone K-30. Drug Dev Ind Pharm. 2006;32:141–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Darandale S, Vavia P. Cyclodextrin based nanosponges of curcumin: formulation and physiochemical characterization. J Inclusion Phenom Macrocyclic Chem. 2013;75:315–22.CrossRefGoogle Scholar
  20. 20.
    Rao M, Shirsath C. Enhancement of bioavailability of non-nucleoside reverse transcriptase inhibitor using nanosponges. AAPS PharmSciTech. 2016;10:1–11.Google Scholar
  21. 21.
    Rao M, Bajaj A, Pardeshi A, Aghav S. Investigation of nanoporous colloidal carrier for solubility enhancement of Cefpodoxime proxetil. J Pharm Res. 2012;5(5):2496–9.Google Scholar
  22. 22.
    Lemboa D, Swaminathan S, Donalisioa M, Trotta F, Cavalli R. Encapsulation of acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent’s antiviral efficacy. Int J Pharm. 2013;443:262–72.CrossRefGoogle Scholar
  23. 23.
    Ansari K, Vavia P, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech. 2011;12:132–46.CrossRefGoogle Scholar
  24. 24.
    Sevukaranjan M, Bachala T, Nair R. Novel inclusion complex of oseltamivir phosphate with beta cyclodextrin physic-chemical characterization. J Pharma Sci Res. 2010;2(9):583–9.Google Scholar
  25. 25.
    Rao M, Bhingole R. Nanosponge based pediatric-controlled release dry suspension of gabapentin for reconstitution. Drug Dev Ind Pharm. 2015;41(12):2029–36.CrossRefPubMedGoogle Scholar
  26. 26.
    Safwat M, Soliman G, Sayed D, Attia M. Gold nanoparticles capped with benzalkonium chloride and poly (ethylene imine) for enhanced loading and skin permeability of 5-fluorouracil. Drug Dev Ind Pharm. 2017;(11):1–16.Google Scholar
  27. 27.
    Hayashida T, Hachiya A, Ode H. Rilpivirine resistance mutation in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. J Antimicrob Chemother. 2016;71(10):2760–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HV drugs. Adv Drug Deliv Rev. 2010;62:491–502.CrossRefPubMedGoogle Scholar
  29. 29.
    Kommavarpupu M, Sunkara M. Preparation and characterization of rilpivirine solid dispersions with the application of enhanced solubility and dissolution rate. J Basic Appl Sci. 2015;4:71–9.Google Scholar
  30. 30.
    Kumar V, Raja J, Bhikshapathi D. Enhancement of solubility and oral bioavailability of poorly soluble drug Rilpivirine by novel self-emulsifying drug delivery system. Am J Pharma Tech Res. 2015;5(3):1–18.Google Scholar
  31. 31.
    Swaminathan S, Vavia P, Trotta F. Formulation of beta cyclodextrin based nanosponges of itraconazole. J Inclusion Phenom Macrocyclic Chem. 2007;57:89–94.CrossRefGoogle Scholar
  32. 32.
    Dora CP, Trotta F, Kushwah V, Devasari N, Singh C, Suresh S, et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2015;5:1–19.Google Scholar
  33. 33.
    Shankar G, Agrawal Y. Formulation and evaluation of β-cyclodextrin based nanosponges of a poorly water soluble drug. J Chem Pharm Res. 2015;7(4):595–604.Google Scholar
  34. 34.
    Trotta F, Shende P, Biasizzo M. Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with b-cyclodextrin and inclusion complexes of ASA with PMDA cross-linked b-cyclodextrin. J Inclusion Phenom Macrocyclic Chem. 2015;3:14–27.Google Scholar
  35. 35.
    Ghosh S, Bomma S, Prasanna L, Vidyadhar S. Method development and validation of Rilpivirine in bulk and tablet doses form by RP-HPLC method. Res J PharmTech. 2013;6(3):1–8.Google Scholar
  36. 36.
    Torne S, Ansari K, Vavia P, Trotta F, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel loaded nanosponges. Drug Deliv. 2010;17(6):419–25.CrossRefPubMedGoogle Scholar
  37. 37.
    Andreza R, Ana F, Delfim S, Francisco V. Preparation and solid state characterization of inclusion complexes formed between miconazole and methyl-β-cyclodextrin. AAPS PharmSciTech. 2008;9(4):1102–9.CrossRefGoogle Scholar
  38. 38.
    Darandale S, Shevalkar G, Vavia P. Effect of lipid composition in propofol formulations: decisive component in reducing the free propofol content and improving pharmacodynamic profiles. AAPS PharmSciTech. 2016:1–10.Google Scholar
  39. 39.
    Bilensoy E, Rouf M, Vural I, Sen M, Hincal A. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β-cyclodextrin complex. AAPS Pharm SciTech. 2006;7(2):54–62.CrossRefGoogle Scholar
  40. 40.
    Manca M, Marco Z, et al. Diclofenac-β-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies. AAPS Pharm SciTech. 2005;6(3):464–72.CrossRefGoogle Scholar
  41. 41.
    Panikumar A, Venkat R, Sunitha G, Babu S, Subrahmanyam C. Development of biorelevant and discriminating method for dissolution of efavirenz and its formulations. Asian J Pharm Clin Res. 2012;5(3):220–3.Google Scholar
  42. 42.
    Bajaj A, Rao M, Pardeshi A, Sal D. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan. AAPS Pharm SciTech. 2012;13:1331–40.CrossRefGoogle Scholar
  43. 43.
    Rao M, Shivpuje S, Godbole R, Shirsath C. Design and evaluation of sustained release matrix tablets using sintered technique. Int J Pharm Sci. 2015;8(2):115–21.Google Scholar
  44. 44.
    Date A, Shibata A, Bruck P, Christopher J. Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLacell lysates. Biomed Chromatogr. 2015;29(5):709–15.CrossRefPubMedGoogle Scholar
  45. 45.
    Cozzia V, Charbe N, Baldelli M, Castoldia S. Development and validation of a chromatographic UV method for the simultaneous quantification of dolutegravir and rilpivirine in human plasma. Drug Monit. 2016:1–8.Google Scholar
  46. 46.
    Castold D, Clementib E, Cozzia V. Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients. J Pharm Anal. 2016;6:396–403.CrossRefGoogle Scholar
  47. 47.
    Singireddy A, Subramanian S. Fabrication of cyclodextrin nanosponges for quercetin delivery: physicochemical characterization, photostability and antioxidant effects. J Mater Sci. 2014;49:8140–53.CrossRefGoogle Scholar
  48. 48.
    Prasasty V, Yulandi A. Structure based design of novel rilpivirine analogues as HIV-1 non- nucleoside reverse transcriptase inhibitors through QSPR and molecular docking. Int J Pharm Sci. 2015;7(11):340–5.Google Scholar
  49. 49.
    Sagawa N, Shikata T. All are polar molecules hydrophilic? Hydration numbers of nitro compounds and nitriles in aqueous solution. Phys Chem Chem Phy. 2014;16(26):1–18.Google Scholar
  50. 50.
    Sanfrutos J, Jaramillo F, Mahmoud A. Divinyl sulfone cross-linked cyclodextrin based polymeric materials: synthesis and applications as sorbents and encapsulating agent. Molecules. 2015;20:3565–81.CrossRefGoogle Scholar
  51. 51.
    Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem. 2012;8:2091–9.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Usach I, Melis V, Peris J. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013;16(1):18567–77.CrossRefPubMedCentralGoogle Scholar
  53. 53.
    Sherje A, Dravyakar B, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: a critical review. Carbohydr Polym. 2017;17:1–45.Google Scholar
  54. 54.
    Shengpeng W, Ruie C, Joe M, Michel R, Meiwan C. mPEG-b-PCL/TPGS mixed micelles for delivery resveratrol in overcoming resistant breast cancer. Expert Opin Drug Deliv. 2015;12(3):361–73.CrossRefGoogle Scholar
  55. 55.
    Sharma N, Madan P, Lin S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a cosurfactant study. As J Pharm Sci. 2016;11(3):404–16.Google Scholar
  56. 56.
    Takahashi A, Veiga F, Ferraz H. Cyclodextrins inclusion complexes characterization—part II: X-ray diffraction, infrared spectroscopy and nuclear magnetic resonance. Int J Pharm Sci Rev Res. 2012;12(1):9–15.Google Scholar
  57. 57.
    Kumar V, Raju J. Solubility enhancement of poorly soluble antiretrovirals by novel self-emulsifying drug delivery system. Int J Pharm Anal Res. 2016;5(2):245–56.Google Scholar
  58. 58.
    Shrinivas P, Sreeja K. Formulation and evaluation of voriconazole loaded nanosponges for oral and topical delivery. Int J Drug Dev Res. 2013;5(1):55–69.Google Scholar
  59. 59.
    Martins M, Calderini F. Host–guest interactions between dapsone and β-cyclodextrin (part II): thermal analysis, spectroscopic characterization, and solubility studies. J Inclusion Phenom Macrocyclic Chem. 2012;74(1):109–16.CrossRefGoogle Scholar
  60. 60.
    Janet C, Olatunji A, Godwin A, Xia W, Khan I. Preparation and characterization of β sitosterol/ β-cyclodextrin crystalline inclusion complexes. J Inclusion Phenom Macrocyclic Chem. 2015;83(1):141–8.Google Scholar
  61. 61.
    Baghel S, Cathcart H, O’Reilly NJ. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105:2527–44.CrossRefPubMedGoogle Scholar
  62. 62.
    Orsolya J’j’r-L, Piroska S´-R’v’s. Amorphization of a crystalline active pharmaceutical ingredient and thermoanalytical measurements on this glassy form. J Therm Anal Calorim. 2010;102:243–7.CrossRefGoogle Scholar
  63. 63.
    James MR. Influence of vitamin E TPGS on the properties of hydrophilic films produced by hot melt extrusion. Int J Pharm. 2000;202(2):63–70.Google Scholar
  64. 64.
    Yaun Y, Lee R. Contact angle and wetting properties. Surf Sci Tec. 2013;51:3–33.CrossRefGoogle Scholar
  65. 65.
    Srivalli K, Mishra B. Improved aqueous solubility and antihypercholesterolemic activity of ezetimibe on formulating with HP-β-Cyclodextrin and hydrophilic auxiliary substances. AAPS PharmSciTech. 2016;17(2):272–83.CrossRefPubMedGoogle Scholar
  66. 66.
    Thakkar H, Desai J. Influence of excipient on drug absorption via modulation of intestinal transporters activity. As J Pharm. 2015;9:69–82.CrossRefGoogle Scholar
  67. 67.
  68. 68.
    Lade J, Avery L, Bumpus N. Human biotransformation of the non-nucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013;57(10):5067–79.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Sosnik A, Augustine R. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them. Adv Drug Deliv Rev. 2016;1-44.  https://doi.org/10.1016/j.addr.2015.12.022:105–20.CrossRefGoogle Scholar
  70. 70.
    Florence A. The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14:259–66.CrossRefPubMedGoogle Scholar
  71. 71.
    Desai M, Labhasetwar V, Amidon G, Levy R. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13:1838–45.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Monica R. P. Rao
    • 1
  • Jagruti Chaudhari
    • 1
  • Francesco Trotta
    • 2
  • Fabrizio Caldera
    • 2
  1. 1.Department of PharmaceuticsAISSMS College of PharmacyPuneIndia
  2. 2.Department of ChemistryUniversity of TorinoTorinoItaly

Personalised recommendations